TW201139446A - Furopyridine compounds and uses thereof - Google Patents

Furopyridine compounds and uses thereof Download PDF

Info

Publication number
TW201139446A
TW201139446A TW100113755A TW100113755A TW201139446A TW 201139446 A TW201139446 A TW 201139446A TW 100113755 A TW100113755 A TW 100113755A TW 100113755 A TW100113755 A TW 100113755A TW 201139446 A TW201139446 A TW 201139446A
Authority
TW
Taiwan
Prior art keywords
methyl
group
cyclopropyl
fluorophenyl
ethyl
Prior art date
Application number
TW100113755A
Other languages
English (en)
Chinese (zh)
Inventor
David Barnes
Rajiv Chopra
Scott Louis Cohen
ji-ping Fu
Mitsunori Kato
Pei-Chao Lu
Mohindra Seepersaud
Wei Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW201139446A publication Critical patent/TW201139446A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
TW100113755A 2010-04-21 2011-04-20 Furopyridine compounds and uses thereof TW201139446A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32649110P 2010-04-21 2010-04-21

Publications (1)

Publication Number Publication Date
TW201139446A true TW201139446A (en) 2011-11-16

Family

ID=44010017

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100113755A TW201139446A (en) 2010-04-21 2011-04-20 Furopyridine compounds and uses thereof

Country Status (9)

Country Link
US (1) US8324239B2 (https=)
EP (1) EP2560976B9 (https=)
JP (1) JP5756850B2 (https=)
CN (1) CN103025738B (https=)
AR (1) AR082453A1 (https=)
ES (1) ES2605039T3 (https=)
TW (1) TW201139446A (https=)
UY (1) UY33348A (https=)
WO (1) WO2011131709A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013004655A (es) 2010-10-26 2013-08-27 Presidio Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑
BR112017023821A2 (pt) 2015-05-06 2018-07-31 Leidos Biomedical Res Inc moduladores de k-ras
BR112019021899A2 (pt) 2017-04-20 2020-08-18 The Regents Of The University Of California moduladores de k-ras
MX2019013562A (es) * 2017-05-19 2020-08-03 Nflection Therapeutics Inc Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
WO2019204449A1 (en) * 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfone moiety
CN108727309B (zh) * 2018-06-20 2023-04-07 天津全和诚科技有限责任公司 一种3-氧杂环丁烷羧酸的合成方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383A (en) 1846-02-10 Improvement in condensing steam and feeding steam-boilers
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
ATE270326T1 (de) 1990-04-04 2004-07-15 Chiron Corp Protease von hepatitis-c-virus
DE69434931T2 (de) 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5703116A (en) 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
EP0859833B1 (en) 1995-09-27 2006-03-01 Emory University Recombinant hepatitis c virus rna replicase
US5759795A (en) 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
JP2001514508A (ja) 1997-03-05 2001-09-11 ユニバーシティー オブ ワシントン C型肝炎ウイルスの複製を選択的に抑制する薬剤を同定するための新規なスクリーニング法
US6228576B1 (en) 1997-12-11 2001-05-08 Smithkline Beecham Corporation Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JPWO2002051849A1 (ja) 2000-12-26 2004-04-22 第一製薬株式会社 Cdk4活性阻害剤
US6951848B2 (en) 2001-03-12 2005-10-04 Millennium Pharmaceuticals, Inc., Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
EP1560582A4 (en) 2002-10-09 2008-03-12 Scios Inc AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE
CN1731993A (zh) 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
MXPA05010802A (es) 2003-04-25 2005-12-14 Univ Cardiff Compuestos heterociclicos para el uso en el tratamiento de infecciones virales.
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス, インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
JP2007529422A (ja) 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ, インコーポレイテッド 抗ウイルス治療
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
JPWO2005082905A1 (ja) 2004-02-26 2007-08-02 協和醗酵工業株式会社 二環性複素環化合物
JP4604086B2 (ja) 2004-05-07 2010-12-22 エグゼリクシス, インコーポレイテッド Rafモジュレーターおよびその使用方法
CA2571881A1 (en) 2004-06-22 2006-01-26 Andreas P. Termin Heterocyclic derivatives for modulation of calcium channels
TW200618800A (en) 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
US20070128270A1 (en) 2005-11-10 2007-06-07 Wyeth Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and method of making the same
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
EP2044061A2 (en) 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
EP2094692B1 (en) 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
US8198311B2 (en) 2006-11-01 2012-06-12 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN101687789A (zh) 2007-02-12 2010-03-31 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
JPWO2008108309A1 (ja) 2007-03-02 2010-06-17 協和発酵キリン株式会社 縮環ピリジン誘導体
PE20090142A1 (es) 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
KR20100016620A (ko) 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 4-알콕시피리다진 유도체
NZ582096A (en) 2007-06-29 2012-05-25 Gilead Sciences Inc Antiviral compounds that inhibit hepatitis c virus (hcv)
WO2009027732A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
WO2009041591A1 (ja) 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
EP2245023B1 (en) 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
JP5756850B2 (ja) 2015-07-29
EP2560976A1 (en) 2013-02-27
EP2560976B9 (en) 2017-06-07
JP2013527842A (ja) 2013-07-04
AR082453A1 (es) 2012-12-12
CN103025738A (zh) 2013-04-03
ES2605039T3 (es) 2017-03-10
WO2011131709A1 (en) 2011-10-27
US8324239B2 (en) 2012-12-04
CN103025738B (zh) 2015-08-19
US20120015907A1 (en) 2012-01-19
UY33348A (es) 2011-12-01
EP2560976B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
ES2897913T3 (es) Compuestos de piridona tetracíclicos como antivirales
ES2940263T3 (es) Compuestos químicos
ES2660914T3 (es) Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD
ES2784477T3 (es) Acidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
TW201139446A (en) Furopyridine compounds and uses thereof
EP3083583B1 (en) Heterocyclic modulators of lipid synthesis and combinations thereof
KR20210110566A (ko) 인돌 ahr 저해제 및 이의 용도
AU2017281903A1 (en) Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
US20210214366A1 (en) Bicyclic heterocycles as fgfr inhibitors
CN111801331A (zh) 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
CA2828478A1 (en) Serine/threonine kinase inhibitors
US20210206760A1 (en) Phenyl-substituted dihydronaphthyridine compound and use thereof
TW201014855A (en) Compounds for the treatment of hepatitis C
TW200946531A (en) HSP90 inhibitors
TW200924751A (en) 2,3-substituted indole derivatives and methods of use thereof
CN103561576A (zh) 脂质合成的杂环调节剂
US20240150343A1 (en) Compound having brd4 inhibitory activity, preparation method therefor and use thereof
TW200936591A (en) Tricyclic compounds and use thereof
TW201632514A (zh) 作為丙型肝炎抑制劑的化合物及其在藥物中的應用
TW201011030A (en) Tricyclic indole derivatives and methods of use thereof
US20230391752A1 (en) Pyrrolidine-3-carboxamide derivatives and related uses
CN109721536B (zh) 苯基取代的稠合三环类化合物及其用途
ES2757052T3 (es) Derivados heterocíclicos bicíclicos
US8716275B2 (en) Compound for the treatment of hepatitis C
TW202237101A (zh) Ctla-4小分子降解劑及其應用